表紙:統合失調症 : パイプライン製品の分析
市場調査レポート
商品コード
232781

統合失調症 : パイプライン製品の分析

Schizophrenia (Central Nervous System) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 513 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.26円
統合失調症 : パイプライン製品の分析
出版日: 2021年09月30日
発行: Global Markets Direct
ページ情報: 英文 513 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

統合失調症は慢性的で重度の、脳障害を引き起こす病気であり、青年期後期か成人早期に症状が現れるのが一般的です。症侯には、妄想、幻覚、解体した会話と行動があります。危険因子として、家族歴、年齢、薬物(精神活性薬)、免疫システムの低下などがあります。治療は抗精神病薬を用います。

当レポートでは、統合失調症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

統合失調症 概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Schizophrenia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021 (Contd..2)
  • Number of Products under Development by Companies, 2021 (Contd..3)
  • Number of Products under Development by Companies, 2021 (Contd..4)
  • Number of Products under Development by Companies, 2021 (Contd..5)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Companies, 2021 (Contd..3)
  • Products under Development by Companies, 2021 (Contd..4)
  • Products under Development by Companies, 2021 (Contd..5)
  • Products under Development by Companies, 2021 (Contd..6)
  • Products under Development by Companies, 2021 (Contd..7)
  • Products under Development by Companies, 2021 (Contd..8)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Target, 2021 (Contd..1)
  • Number of Products by Stage and Target, 2021 (Contd..2)
  • Number of Products by Stage and Target, 2021 (Contd..3)
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..2)
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..3)
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Schizophrenia - Pipeline by 3Z ehf, 2021
  • Schizophrenia - Pipeline by AbbVie Inc, 2021
  • Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Adamed Sp zoo, 2021
  • Schizophrenia - Pipeline by Adare Pharma Solutions, 2021
  • Schizophrenia - Pipeline by Adeptio Pharmaceuticals Ltd, 2021
  • Schizophrenia - Pipeline by AgeneBio Inc, 2021
  • Schizophrenia - Pipeline by AgoneX Biopharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Alexza Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Athersys Inc, 2021
  • Schizophrenia - Pipeline by Autifony Therapeutics Ltd, 2021
  • Schizophrenia - Pipeline by Avanir Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Avicanna Inc, 2021
  • Schizophrenia - Pipeline by Avineuro Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by BCWorld Pharm Co Ltd, 2021
  • Schizophrenia - Pipeline by Beloteca Inc, 2021
  • Schizophrenia - Pipeline by Benuvia Therapeutics Inc, 2021
  • Schizophrenia - Pipeline by Biogen Inc, 2021
  • Schizophrenia - Pipeline by BioXcel Therapeutics Inc, 2021
  • Schizophrenia - Pipeline by Boehringer Ingelheim International GmbH, 2021
  • Schizophrenia - Pipeline by Bristol-Myers Squibb Co, 2021
  • Schizophrenia - Pipeline by Celon Pharma SA, 2021
  • Schizophrenia - Pipeline by Cerevance Inc, 2021
  • Schizophrenia - Pipeline by Cerevel Therapeutics Holdings Inc, 2021
  • Schizophrenia - Pipeline by Curemark LLC, 2021
  • Schizophrenia - Pipeline by CuroNZ Ltd, 2021
  • Schizophrenia - Pipeline by Cyclerion Therapeutics Inc, 2021
  • Schizophrenia - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
  • Schizophrenia - Pipeline by Daya Drug Discoveries Inc, 2021
  • Schizophrenia - Pipeline by Delpor Inc, 2021
  • Schizophrenia - Pipeline by Denovo Biopharma LLC, 2021
  • Schizophrenia - Pipeline by Echo Pharmaceuticals BV, 2021
  • Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Gabather AB, 2021
  • Schizophrenia - Pipeline by Genentech USA Inc, 2021
  • Schizophrenia - Pipeline by Genochem SAS, 2021
  • Schizophrenia - Pipeline by GP Pharm SA, 2021
  • Schizophrenia - Pipeline by H. Lundbeck AS, 2021
  • Schizophrenia - Pipeline by IntelGenx Corp, 2021
  • Schizophrenia - Pipeline by Intra-Cellular Therapies Inc, 2021
  • Schizophrenia - Pipeline by INVENT Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Io Therapeutics Inc, 2021
  • Schizophrenia - Pipeline by Jaguar Health Inc, 2021
  • Schizophrenia - Pipeline by Jazz Pharmaceuticals Plc, 2021
  • Schizophrenia - Pipeline by Jiangsu Enhua Pharmaceutical Group Co Ltd, 2021
  • Schizophrenia - Pipeline by Jiangsu Nhwa Pharmaceutical Co Ltd, 2021
  • Schizophrenia - Pipeline by Johnson & Johnson, 2021
  • Schizophrenia - Pipeline by Karuna Therapeutics Inc, 2021
  • Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi SA, 2021
  • Schizophrenia - Pipeline by LB Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Lead Discovery Center GmbH, 2021
  • Schizophrenia - Pipeline by Livzon Pharmaceutical Group Co Ltd, 2021
  • Schizophrenia - Pipeline by Lohocla Research Corp, 2021
  • Schizophrenia - Pipeline by Luye Pharma Group Ltd, 2021
  • Schizophrenia - Pipeline by Lyndra Therapeutics Inc., 2021
  • Schizophrenia - Pipeline by MapLight therapeutics Inc, 2021
  • Schizophrenia - Pipeline by MedinCell SA, 2021
  • Schizophrenia - Pipeline by Mental-Heal Ltd, 2021
  • Schizophrenia - Pipeline by Merck & Co Inc, 2021
  • Schizophrenia - Pipeline by Midatech Pharma Plc, 2021
  • Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
  • Schizophrenia - Pipeline by Nanomi BV, 2021
  • Schizophrenia - Pipeline by Neonc Technologies Inc, 2021
  • Schizophrenia - Pipeline by Neurocea Pharmaceuticals, 2021
  • Schizophrenia - Pipeline by Neurocrine Biosciences Inc, 2021
  • Schizophrenia - Pipeline by NeurOp Inc, 2021
  • Schizophrenia - Pipeline by NeuroSolis Inc, 2021
  • Schizophrenia - Pipeline by Newron Pharmaceuticals SpA, 2021
  • Schizophrenia - Pipeline by Novartis AG, 2021
  • Schizophrenia - Pipeline by Omeros Corp, 2021
  • Schizophrenia - Pipeline by Oryzon Genomics SA, 2021
  • Schizophrenia - Pipeline by Otsuka Holdings Co Ltd, 2021
  • Schizophrenia - Pipeline by Otsuka Pharmaceutical Co Ltd, 2021
  • Schizophrenia - Pipeline by OWP Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Ra Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Richter Gedeon Nyrt, 2021
  • Schizophrenia - Pipeline by Saniona AB, 2021
  • Schizophrenia - Pipeline by Schrodinger Inc, 2021
  • Schizophrenia - Pipeline by Shanghai Zhongze Medicine Tech Co Ltd, 2021
  • Schizophrenia - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2021
  • Schizophrenia - Pipeline by Siragen Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Sirtsei Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by SkySea Pharmaceutical Inc, 2021
  • Schizophrenia - Pipeline by Sosei Group Corp, 2021
  • Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2021
  • Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Suven Life Sciences Ltd, 2021
  • Schizophrenia - Pipeline by SyneuRx International Corp, 2021
  • Schizophrenia - Pipeline by Taho Pharmaceuticals Ltd, 2021
  • Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
  • Schizophrenia - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
  • Schizophrenia - Pipeline by Terran Biosciences Inc, 2021
  • Schizophrenia - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
  • Schizophrenia - Pipeline by The Greater Cannabis Company Inc, 2021
  • Schizophrenia - Pipeline by Therapeutic Solutions International Inc, 2021
  • Schizophrenia - Pipeline by Valentec, 2021
  • Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc, 2021
  • Schizophrenia - Pipeline by Verge Genomics Inc, 2021
  • Schizophrenia - Pipeline by Viatris Inc, 2021
  • Schizophrenia - Pipeline by Vitality Biopharma Inc, 2021
  • Schizophrenia - Pipeline by Whan In Pharm Co Ltd, 2021
  • Schizophrenia - Pipeline by Zhejiang Jingxin Pharmaceutical Co Ltd, 2021
  • Schizophrenia - Pipeline by Zysis Ltd, 2021
  • Schizophrenia - Dormant Projects, 2021
  • Schizophrenia - Dormant Projects, 2021 (Contd..1)
  • Schizophrenia - Dormant Projects, 2021 (Contd..2)
  • Schizophrenia - Dormant Projects, 2021 (Contd..3)
  • Schizophrenia - Dormant Projects, 2021 (Contd..4)
  • Schizophrenia - Dormant Projects, 2021 (Contd..5)
  • Schizophrenia - Dormant Projects, 2021 (Contd..6)
  • Schizophrenia - Dormant Projects, 2021 (Contd..7)
  • Schizophrenia - Dormant Projects, 2021 (Contd..8)
  • Schizophrenia - Dormant Projects, 2021 (Contd..9)
  • Schizophrenia - Dormant Projects, 2021 (Contd..10)
  • Schizophrenia - Discontinued Products, 2021
  • Schizophrenia - Discontinued Products, 2021 (Contd..1)
  • Schizophrenia - Discontinued Products, 2021 (Contd..2)

List of Figures

List of Figures

  • Number of Products under Development for Schizophrenia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC13073IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Drugs In Development, 2021, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 12, 18, 26, 5, 65, 17 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 5 and 1 molecules, respectively.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Schizophrenia - Overview
  • Schizophrenia - Therapeutics Development
  • Schizophrenia - Therapeutics Assessment
  • Schizophrenia - Companies Involved in Therapeutics Development
  • Schizophrenia - Drug Profiles
  • Schizophrenia - Dormant Projects
  • Schizophrenia - Discontinued Products
  • Schizophrenia - Product Development Milestones
  • Appendix